Longitudinal Regional Flortaucipir Profiles in Preclinical Alzheimer’s Disease: Evaluation using A4 phase 3 trial with Solanezumab
Vikas Kotari, Karen Chilcott Holdridge, Roy Yaari, Aaron P Schultz, Keith A Johnson, Paul S. S. Aisen, Reisa A Sperling, John R. Sims, Sergey Shcherbinin · 2025
Read Longitudinal Regional Flortaucipir Profiles in Preclinical Alzheimer’s Disease: Evaluation using A4 phase 3 trial with Solanezumab by Vikas Kotari, Karen Chilcott Holdridge, Roy Yaari, Aaron P Schultz, Keith A Johnson, Paul S. S. Aisen, Reisa A Sperling, John R. Sims, Sergey Shcherbinin (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715687.txt.
Description
Vikas Kotari and co-authors chart how flortaucipir PET signal, a scan measure of tau, grows over time in adults who have amyloid buildup but no symptoms yet. The data come from the A4 trial, a large phase 3 test of the drug solanezumab. Scans were taken at baseline and three later visits out to week 240. The team grouped brain regions into early, middle, and late sets, ordered by how tau pathology is thought to spread.
Early and middle regions changed most at the first follow-up check, and the middle region led at later checks. A whole-brain score moved less than the regional scores at each visit. Most participants stayed below the line for a positive whole-brain reading throughout. A high baseline amyloid load most strongly drove growth in the middle region. Regional scores may track silent disease better than one global score.
Catalog record
| CREATOR | Vikas Kotari, Karen Chilcott Holdridge, Roy Yaari, Aaron P Schultz, Keith A Johnson, Paul S. S. Aisen, Reisa A Sperling, John R. Sims, Sergey Shcherbinin |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |